Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
MHLW’s COVID-19 Guide Adds Chugai’s Cocktail Therapy
The Ministry of Health, Labor and Welfare (MHLW) has updated its COVID-19 care guide, adding new complications for the disease and Chugai Pharmaceutical’s new antibody cocktail therapy to the approved drug list.In the 5.2 edition of the guide, the MHLW…
To read the full story
Related Article
- MHLW’s COVID-19 Guide Recommends against Camostat after Trial Failures
July 7, 2021
- Olumiant Added to MHLW’s COVID-19 Guide as Approved Drug
May 28, 2021
- Adrenomedullin, Baricitinib Added to MHLW’s COVID-19 Guide
December 8, 2020
- MHLW Erases Hydroxychloroquine, 4 Other Drugs from COVID-19 Treatment Guide
September 10, 2020
- Dexamethasone Added to MHLW’s COVID-19 Guide
July 27, 2020
- MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
- MHLW Issues COVID-19 Treatment Guide
March 19, 2020
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…